Mode
Text Size
Log in / Sign up

Meta-analysis finds allergic rhinitis associated with 2.75-fold increased migraine risk

Meta-analysis finds allergic rhinitis associated with 2.75-fold increased migraine risk
Photo by ClinicalPulse / Unsplash
Key Takeaway
Consider screening for migraine in patients with allergic rhinitis, but recognize this is observational association evidence.

This systematic review and meta-analysis examined the association between allergic rhinitis and migraine risk across 10 observational studies involving more than 4.8 million participants. The analysis compared individuals with allergic rhinitis to those without the condition, with migraine as the primary outcome.

The main finding was a significant association between allergic rhinitis and increased migraine risk, with an odds ratio of 2.75 (95% confidence interval, 1.80–4.19). This translates to an estimated excess of 23–82 migraine cases per 1,000 individuals with allergic rhinitis. Safety and tolerability data were not reported in the included studies.

Key limitations include high statistical heterogeneity (I² = 99%) among the included studies and the observational nature of all evidence, which prevents causal inference. The review did not report funding sources or conflicts of interest. While this evidence suggests clinicians should be aware of the association between allergic rhinitis and migraine, the findings should be interpreted cautiously given the methodological constraints.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundAllergic rhinitis (AR) and migraine are common chronic conditions that significantly impact patients’ quality of life. Although observational studies suggest a potential link between AR and increased migraine risk, evidence remains inconsistent.ObjectiveTo systematically evaluate the association between AR and migraine risk through a comprehensive meta-analysis.MethodsDatabases including PubMed, Web of Science, Scopus, and CNKI were systematically searched up to July 2025. Observational studies investigating the association between AR and migraine were included. Data extraction, quality assessment, and meta-analysis were performed following PRISMA guidelines. Random-effects models were utilized, and subgroup analyses were conducted (by study design, age group, and effect measure). Sensitivity analyses (exclusion of cross-sectional studies, restriction to large-sample studies, use of unadjusted estimates, and leave-one-out procedures) were conducted to assess robustness. Publication bias was evaluated using funnel plots, trim-and-fill analysis, and Egger’s regression test. Additional analyses included meta-regression to explore sources of heterogeneity, cumulative meta-analysis to assess temporal trends, and conversion of relative effects to absolute risk estimates.ResultsTen studies involving more than 4.8 million participants met the inclusion criteria. Pooled results indicated a significantly elevated risk of migraine among individuals with AR (OR = 2.75; 95% CI, 1.80–4.19; I2 = 99%). Subgroup analyses demonstrated consistent findings across study designs, age groups, and analytical approaches. Sensitivity analyses indicated stable results, with no single study markedly influencing the pooled estimate. Meta-regression suggested that study design, age group, and sample size explained part of the heterogeneity. Cumulative analysis showed that early small-sample studies overestimated the association, while larger recent studies stabilized the effect at 2–3 fold risk. Absolute effect estimates indicated an excess of 23–82 migraine cases per 1,000 individuals with AR, with population attributable fractions ranging from 6.8 to 18.1%.ConclusionAllergic rhinitis is significantly associated with an increased risk of migraine. Clinicians should be aware of this association and consider integrated management strategies for patients with comorbid AR and migraine.Systematic review registrationINPLASY2025110052.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.